Xenobiotic metabolizing and transporter genes: Gene-gene interactions in schizophrenia and related disorders

Pharmacogenomics

Volumn 11, Issue 12, 2010, Pages 1725-1731

  Gass, Patricia ^a,b,c   Mas, Sergi ^a,b,c   Lvarez, Santi ^a,b,c   Trias, Gemma ^a   Bioque, Miquel ^b,c,d   Oliveira, Cristina ^b,d   Bernardo, Miquel ^a,b,c,d   Lafuente, Amalia ^a,b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

ABCB1; CYP1A2; CYP2D6; CYP3A5; epistasis; pharmacogenetics; schizophrenia

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; GUANOSINE; MULTIDRUG RESISTANCE PROTEIN 1; THYMINE; XENOBIOTIC AGENT;

ACUTE PSYCHOSIS; ADULT; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; DELUSIONAL DISORDER; EPISTASIS; FEMALE; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HOMEOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; XENOBIOTIC METABOLISM;

ADULT; BIOLOGICAL TRANSPORT; BRAIN; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DATA INTERPRETATION, STATISTICAL; EPISTASIS, GENETIC; FEMALE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PSYCHOTIC DISORDERS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SCHIZOPHRENIA, PARANOID; XENOBIOTICS;

EID: 78650371598     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.158     Document Type: Article

References (34)

1. Moore JH, Gilbert JC, Tsai CT et al.: A fexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. J. Theor. Biol. 241, 252-261 (2006).
2. Moore JH, Williams SM: Traversing the conceptual divide between biological and statistical epistasis: systems biology and a more modern synthesis. Bioessays 27, 637-646 (2005).
3. Dutheil F, Dauchy S, Diry M et al.: Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab. Dispos. 37, 1528-1538 (2009).
4. Dauchy S, Dutheil F, Weaver RJ et al.: ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J. Neurochem. 107, 1518-1528 (2008).
5. Dutheil F, Beaune P, Loriot MA: Xenobiotic metabolizing enzymes in the central nervous system: contribution of cytochrome P450 enzymes in normal and pathological human brain. Biochimie 90, 426-436 (2008).
6. Bozina N, Rojnic Kuzman M, Medved V, Jovanovic N, Sertic J, Hotujac L: Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J. Psychiatry Res. 42, 89-97 (2008).
7. Qian W, Homma M, Itagaki F et al.: MDR1 gene polymorphism in Japanese patients with schizophrenia and mood disorders including depression. Biol. Pharm. Bull. 29, 2446-2450 (2006).
8. Dorado P, Peñas-Lledó EM, Llerena A: CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. Pharmacogenomics 8, 1597-1608 (2007).
9. Du J, Xu Y, Duan S et al.: A case-control association study between the CYP3A4 and CYP3A5 genes and schizophrenia in the Chinese Han population. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 1200-1204 (2009).
10. Llerena A, Dorado P, Peñas-Lledó EM, Cáceres MC, De la Rubia A: Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. Pharmacogenomics J. 7, 408-410 (2007).
11. Peñas-LLedó EM, Dorado P, Pacheco R, González I, Llerena A: Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers. Pharmacogenomics 10, 1111-1120 (2009).
12. First MB, Spitzer RL, Williams JBW, Gibbon M: Structured Clinical Interview for DSM-IV- Patients edition (SCID-P). American Psychiatric Press, Washington, DC, USA, (1994).
13. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. American Psychiatric Press, Washington, DC, USA (1994).
14. Mas S, Bernardo M, Gassó P et al.: A functional variant provided further evidence for the association of ARVCF with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet 153B(5), 1052-1059 (2010).
15. Alvarez S, Mas S, Gassó P, Bernardo M, Parellada E, Lafuente A: Lack of association between schizophrenia and polymorphisms in dopamine metabolism and transport genes. Fundam. Clin. Pharmacol. 24(6), 741-747 (2010).
16. Crescenti A, Mas S, Gassó P, Baiget M, Bernardo M, Lafuente A: Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis. Clin. Exp. Pharmacol. Physiol. 34, 992-997 (2007).
17. Tiwari AK, Deshpande SN, Rao AR et al.: Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J. 5, 60-69 (2005).
18. González JR, Armengol L, Solé X et al.: SNPassoc: an R package to perform whole genome association studies. Bioinformatics 23, 644-645 (2007).
19. Lou XY, Chen GB, Yan L et al.: A generalized combinatorial approach for detecting gene-by-gene and gene-by-environment interactions with application to nicotine dependence. Am. J. Hum. Genet. 80, 1125-1137 (2007).
20. Moore JH, Williams SW: New strategies for identifying gene-gene interactions in hypertension. Ann. Med. 34, 88-95 (2002).
21. Heidema AG, Boer JM, Nagelkerke N, Mariman EC, van der A DL, Feskens EJ: The challenge for genetic epidemiologists: how to analyze large numbers of SNPs in relation to complex diseases. BMC Genet. 7, 23 (2006).
22. Julià A, Moore J, Miquel L et al.: Identifcation of a two-loci epistatic interaction associated with susceptibility to rheumatoid arthritis through reverse engineering and multifactor dimensionality reduction. Genomics 90, 6-13 (2007).
23. Kwan P, Sills GJ, Butler E, Gant TW, Meldrum BS, Brodie MJ: Regional expression of multidrug resistance genes in genetically epilepsy-prone rat brain after a single audiogenic seizure. Epilepsia 43, 1318-1323 (2002).
24. Furuno T, Landi MT, Ceroni M et al.: Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 12, 529-534 (2002).
25. Benyamina A, Bonhomme-Faivre L, Picard V, et al.: Association between ABCB1 C3435T polymorphism and increased risk of cannabis dependence. Prog Neuropsychopharmacol. Biol. Psychiatry 33, 1270-1274 (2009).
26. Ekelund J, Lichtermann D, Hovatta I et al. Genome-wide scan for schizophrenia in the Finnish population: evidence for a locus on chromosome 7q22. Hum. Mol. Genet. 9, 1049-1057 (2000).
27. Monti JM, Monti D. Sleep disturbance in schizophrenia. Int. Rev. Psychiatry 17, 247-253 (2005).
28. Afonso P, Brissons S, Figueira ML, Paiva T: Discrepant nocturnal melatonin levels in monozygotic twins discordant for schizophrenia and its impact on sleep. Schizophr. Res. 120(1-3), 227-228. (2010).
29. Freedman R, Leonard S, Olincy A et al.: Evidence for the multigenic inheritance of schizophrenia. Am. J. Med. Genet. 105, 794-800 (2001).
30. Gan SH, Ismail R, Wan Adnan WA, Zulmi W, Kumaraswamy N, Larmie ET: Relationship between Type A and B personality and debrisoquine hydroxylation capacity. Br. J. Clin. Pharmacol. 57, 785-789 (2004).
31. Roberts RL, Luty SE, Mulder RT, Joyce PR, Kennedy MA: Association between cytochrome P450 2D6 genotype and harm avoidance. Am. J. Med. Genet. B Neuropsychiatr. Genet. 127, 90-93 (2004).
32. González I, Peñas-Lledó EM, Pérez B, Dorado P, Alvarez M, Llerena A: Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics 9, 833-840 (2008).
33. Llerena A, Edman G, Cobaleda J, Benítez J, Schalling D, Bertilsson L: Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr. Scand. 87, 23-28 (1993).
34. Kirchheiner J, Seeringer A, Godoy AL et al.: CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol. Psychiatry (2010) (Epub ahead of print).